SCHEMBL15465246

SCHEMBL15465246

Nc1ncccc1C1=CCCCC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
PSMB5 P28074 2/20 0.40
PTGS2 P35354 1/20 0.40
PDE10A Q9Y233 1/20 0.39
F2RL1 P55085 1/20 0.39
FFAR2 O15552 2/20 0.38
MKNK1 Q9BUB5 1/20 0.38
MKNK2 Q9HBH9 1/20 0.38
KDR P35968 1/20 0.38
JAK2 O60674 1/20 0.38
JAK1 P23458 1/20 0.38
JAK3 P52333 1/20 0.38
ATR Q13535 1/20 0.38
CCNE1 P24864 1/20 0.38
CDK2 P24941 1/20 0.38
CYP1A2 P05177 1/20 0.37
GRM5 P41594 1/20 0.37
NOS3 P29474 2/20 0.37
NOS1 P29475 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25343836 0.95 F2RL1 (0.43) MAP4K4TDP1PSMB5PTGS2PDE10A
SCHEMBL15465608 0.79 PSMB5 (0.47) TDP1PSMB5PTGS2PDE10AF2RL1
SCHEMBL12030457 0.79 TDP1 (0.41) TDP1PSMB5PTGS2PDE10AF2RL1
SCHEMBL3083160 0.76 JAK2 (0.44) TDP1FFAR2JAK2JAK1JAK3
SCHEMBL14878660 0.75 PDE10A (0.57) PDE10A
SCHEMBL11815728 0.75 PTGS2 (0.59) TDP1PSMB5PTGS2F2RL1FFAR2
SCHEMBL14151558 0.74 KDM4E (0.45) TDP1PTGS2PDE10AF2RL1ATR
SCHEMBL5189044 0.74 PTGS2 (0.47) TDP1PSMB5PTGS2F2RL1FFAR2
SCHEMBL2250102 0.73 BACE1 (0.42) MAP4K4PDE10ACDK2
SCHEMBL18278895 0.73 HTR2C (0.50) PDE10AGRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3144300-B1 METHODS OF PRODUCING 4-CYCLOALKYLOXYBENZENESULFONAMIDES DAIICHI SANKYO CO LTD (JP) 2017-12-20 EP disclosed
US-9845313-B2 Cycloalkane derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2017-12-19 US disclosed
EP-3144300-A1 METHODS OF PRODUCING 4-CYCLOALKYLOXYBENZENESULFONAMIDES Daiichi Sankyo Company, Limited (JP) 2017-03-22 EP disclosed
US-20170001984-A1 CYCLOALKANE DERIVATIVES DAIICHI SANKYO COMPANY, LIMITED (JP) 2017-01-05 US disclosed
US-9493448-B2 Cycloalkane derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-11-15 US disclosed
EP-2813491-B1 CYCLOALKANE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2016-11-02 EP disclosed
EP-2813491-A1 CYCLOALKANE DERIVATIVE Daiichi Sankyo Co., Ltd. (JP) 2014-12-17 EP disclosed
US-8889741-B2 Cycloalkane derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-11-18 US disclosed
US-20140045862-A1 Cycloalkane Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170001984-A1 CYCLOALKANE DERIVATIVES TRPV1, TRPA1, SCNN1A MAP4K4 2670/4885TDP1 3007/4885PSMB5 1728/4885
US-20140045862-A1 Cycloalkane Derivatives TRPV1, TRPA1, SCNN1A MAP4K4 2670/4885TDP1 3007/4885PSMB5 1728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.